Ozempic-style obesity drug bypasses neurons, avoids nausea and vomiting side effects
SMRTR summary
Researchers at Syracuse University have developed a new weight loss drug that targets brain support cells instead of neurons, avoiding the nausea and vomiting common in GLP-1 medications like Ozempic. Their modified peptide called TDN works on downstream pathways that regulate hunger without triggering digestive distress, showing promising results in animal tests with potential human trials by 2026.
SMRTR provides this summary for quick context. The original article belongs to Interesting Engineering.
Read the original article